Tags: Allegro Diagnostics, bronchogen, diagnosis, lung cancer
add a comment
On October 23rd MBBP client Allegro Diagnostics, Inc. announced positive results from the AEGIS I (Airway Epithelium Gene Expression In the Diagnosis of Lung Cancer) clinical trial. The trial was meant to test the diagnostic accuracy of BronchoGen™, Allegro’s lead genomic test intended to bring early detection to the standard of care for lung cancer. Allegro Diagnostics’ molecular testing platform utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer. Gerard Silvestri, M.D., member of Allegro Diagnostics’ Clinical & Scientific Advisory Board and a principal investigator of the AEGIS studies, had this to say of the results:
These positive results show significantly higher sensitivity and negative predictive value in lung cancer diagnoses using BronchoGen™ in combination with bronchoscopy than by bronchoscopy alone. The data suggest that BronchoGen™ has the ability to aid bronchoscopy in better predicting the presence or absence of cancer, possibly avoiding costly and risky invasive procedures.
To learn more about the clinical trial and its results, please read Allegro Diagnostics’ full press release.
Tags: Allegro Diagnostics, boston university, innovator of the year
add a comment
On July 19th, MBBP client Boston University hosted its second annual Tech, Drugs and Rock & Roll event which 500 industry professionals, entrepreneurs and BU community members attended for an evening of food, drinks, music and technology. BU provost and chief academic officer Jean Morrison also presented the 2011 Innovator of the Year award to School of Medicine associate professor and MBBP client Allegro Diagnostics founder Avrum Spira. The award recognizes BU faculty members whose cutting-edge research and ideas lead to the formation of companies that benefit society at large. Dr. Spira was selected for his research on lung cancer, chronic obstructive pulmonary disease (COPD), and the effects of smoking on airway epithelial cell-gene expression. Morrison had this to say of the honoree:
Professor Spira is an entrepreneurial scientist, whose practical approach to science has led to the formation of Allegro Diagnostics, a start-up company intent on producing beneficial molecular diagnostics for detecting lung cancer. His accomplishments in the past year include 14 peer-reviewed papers published, one invention disclosure, two patent filings, over $3.5 million in NIH funding, and $8.9 million invested in Allegro Diagnostics.
Please visit Allegro Diagnostics to learn more about their initiatives.
Tags: Allegro Diagnostics, boston university, university of utah foundation
add a comment
On June 29th, MBBP client Allegro Diagnostics, Inc. announced that it has entered into an exclusive license agreement with MBBP client Boston University and the University of Utah Foundation for intellectual property related to Allegro Diagnostics’ molecular testing platform which utilizes a genomic biomarker to detect early signs of lung cancer. Mike Webb, President and CEO of Allegro Diagnostics, describes the agreement:
Allegro Diagnostics is committed to bringing early lung cancer detection to the standard of care. The licensing agreement with Boston University and the University of Utah Foundation helps us to achieve that goal by supporting our continued advancement of this breakthrough platform, including the planned commercial launch of BronchoGen™ in the first half of 2012.
For more information please read the full press release.
Tags: Allegro Diagnostics, bioinformatics, medical diagnostics
1 comment so far
MBBP Client Allegro Diagnostics will begin marketing a “microarray-based test” for early-stage lung cancer. Allegro CEO Dan Rippy intends to offer a test called BronchoGen as a unique service through its clinical laboratory. BronchoGen is an 80-gene biomarker assay that can detect and rule out the presence of cancer cells. This screening will complement bronchoscopy, a procedure in which a clinician examines a patients airways with a scope in order to rule out the presence of cancer. Rippy hopes BronchoGen will be available by the end of 2010.
For the full article, please see GenomeWeb Daily News.
For more information on BronchoGen, please visit Allegro Diagnosics.